Angiotensin II

Identification

Name

Angiotensin II

Accession Number

DB11842

Description

Angiotensin II is under investigation for the treatment of Sepsis, Septic Shock, Diabetes Mellitus, and Acute Renal Failure. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy.

As of December 21, 2017 the FDA approved La Jolla Pharmaceutical's Giapreza (angiotensin II) Injection for Intravenouse Infusion for the indication of acting as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. The novelty of the medication lies in the fact that it is the first and only use of synthetic human angiotensin II to help maintain body blood pressure.

Shock is the inability to maintain blood flow to vital tissues and the potential resultant organ failure and death within hours, no matter young or o ld. As distributive shock is the most common type of shock in the inpatient setting and affects up to one third of patients in the intensive care unit, the FDA determined that there is a need for treatment options for critically ill hypotensive patients who do not adequately respond to currently available therapies.

Type

Small Molecule

Groups

Approved, Investigational

Structure

Download

MOLSDFPDBSMILESInChI

Similar Structures

Structure for Angiotensin II (DB11842)

×

Close

Weight

Average: 1046.1786
Monoisotopic: 1045.534514801

Chemical Formula

C₅₀H₇₁N₁₃O₁₂

Synonyms

• 5-isoleucine-angiotensin II
• 5-L-isoleucineangiotensin II
• Angiotensin
• Angiotensin II
• Angiotensin II (human)
• Angiotonin
• Human angiotensin II
• Hypertensin
• Ile5-angiotensin II
• isoleucine5-angiotensin II

Pharmacology

Indication

Angiotensin II is a vasoconstrictor indicated for increasing blood pressure in adults with septic or other distributive shock ^Label.

Associated Conditions

• Hypotension

Contraindications & Blackbox Warnings

Learn about our commercial Contraindications & Blackbox Warnings data.

Learn More

Pharmacodynamics

Angiotensin II is a naturally occurring peptide hormone of the renin-angiotensin-aldosterone-system (RAAS) that has the capacity to cause vasoconstriction and an increase in blood pressure in the human body. ^Label

In the RAAS, juxtaglomerular cells of the renal afferent arteriole synthesize the proteolytic enzyme renin. Although stored in an inactive form called pro-renin, decreases in arterial blood pressure or extracellular fluid volume depletion can cause various enzymatic reactions to release active renin into the systemic circulation and surrounding tissues. Such renin release allows for the production of the alpha-2-globulin angiotensinogen predominantly in the liver and to some extent, the kidneys and other organs. ¹

Angiotensin I, itself a decapeptide with weak biological activity, is produced from angiotensinogen and then quickly converted to angiotensin II by angiotensin converting enzymes (ACE). Consequently, angiotensin II demonstrates its strong vasopressor activity when it is rapidly degraded by aminopeptidases A and M into further entities like angiotensin III and angiotensin IV, respectively. Such species like angiotensin III can then bind and interact with specific G protein coupled receptors like angiotensin receptor 1, or AT-1 ¹ where strong vasoconstricson can occur. ¹

Furthermore, in the ATHOS-3 clinical trial, for the 114 (70%) patient subjects in the angiotensin II arm who reached the target mean arterial pressure (MAP) at Hour 3, the median time to reach the target MAP endpoint was approximately 5 minutes. The angiotensin II was titrated to effect for each individual patient. ^Label.

Mechanism of action

As part of the renin-angiotensin-aldosterone-system (RAAS), angiotensin II raises blood pressure by vasoconstriction, increased aldosterone release by the adrenal zona glomerulosa, sodium and water reabsorption in the proximal tubular cells, and vasopressin secretion ^Label,1

The direct action of angiotensin II on surrounding vessel walls is facilitated by binding to the G-protein-coupled angiotensin II receptor type 1 (AT-1) on vascular smooth muscle cells, which stimulates Ca2+/calmodulin-dependent phosphorylation of myosin and causes smooth muscle contraction that results in vasoconstriction ^Label,1.

The RAAS is ultimately regulated by a negative feedback effect of angiotensin II on renin production by the juxtaglomerular cells of the renal afferent arteriole. Unresuscitated septic shock associated with marked hypovolemia, extracellular fluid volume depletion, decreased cardiac output, low arterial blood pressure and decreased systemic vascular resistance causes an increase in renin secretion by the juxtaglomerular cells, resulting in elevated angiotensin II plasma levels and an increased secretion of aldosterone from the adrenal cortex. Angiotensin II binding to AT-1 receptors causes dose-dependent vasoconstriction of both afferent and efferent glomerular arterioles. The most pronounced effect of angiotensin II results on efferent arterioles, resulting in reduced renal blood flow and increased glomerular filtration pressure. ¹

Target	Actions	Organism
AType-1 angiotensin II receptor	agonist	Humans

Absorption

Following the intravenous infusion of angiotensin II in adult patients with septic or other distributive shock, the serum levels of angiotensin II observed were similar at baseline and hour 3 after the intravenous infusion. After 3 hours of treatment, the serum level of angiotensin I (the angiotensin II precursos peptide) is however, reduced by about 40% ^Label.

Volume of distribution

The official prescribing information for angiotensin II notes that no specific studies have yet been conducted that examine the distribution of angiotensin II ^Label.

Protein binding

Not Available

Metabolism

It is metabolized by aminopeptidase A and angiotensin converting enzyme 2 to angiotensin-(2-8) [angiotensin III] and angiotensin-(1-7), respectively in plasma, erythrocytes and many of the major organs (i.e. intestine, kidney, liver and lung). Angiotensin II type 1 receptor (AT1) mediated activity of angiotensin III is approximately 40% of angiotensin II; however, aldosterone synthesis activity is similar to angiotensin II. Angiotensin-(1-7) exerts the opposite effects of angiotensin II on AT1 receptors and causes vasodilation ^Label.

Nevertheless, the official prescribing information also notes that no formal studies have been conducted that examine the metabolism of angiotensin II ^Label.

Hover over products below to view reaction partners

• Angiotensin II
  • Angiotensin 1-7
  • Angiotensin III

Route of elimination

The official prescribing information notes that no specific studies have been conducted that examine the elimination of angiotensin II.

Half-life

The plasma half-life of intravenously administered angiotensin II is less than one minute ^Label.

Clearance

The official prescribing information notes that the clearnace of angiotensin II is not dependent on hepatic function or renal function ^Label.

Adverse Effects

Learn about our commercial Adverse Effects data.

Learn More

Toxicity

Overdose with angiotensin II would be expected to result in hypertension, necessitating close monitoring and supportive care ^Label. Effects are also expected to be brief as the half-life of angiotensin II is less than one minute ^Label.

In the ATHOS-3 clinical study there was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received angiotensin II compared to placebo treated patients. The major imbalance was in deep venous thromboses - which prompts the potential need to use concurrent venous thromboembolism (VTE) prohphylaxis ^Label.

Adverse effects of noticeable potential (>= 10%) include thromboembolic events (ie. like deep vein thrombosis) including arterial and venous thrombotic events, thrombocytopenia, tachycardia, and fungal infection. Effects whose potential are < 10% include delirium, acidosis, hyperglycemia, peripheral ischemia ^Label.

Concomitant use of angiotensin converting enzymes (ACE) inhibitors may increase the response of angiotensin II ^Label.

Concomitant use of angiotensin II blockers (ARBs) may decrease the response to angiotensin II ^Label.

There are no formal data regarding the safe use of angiotensin II in pregnant women. However, septic or other distributive shock is a medical emergency that can be fatal if left untreated. Delaying treatment in pregnant women with hypotension associated with septic or otherdistributive shock is likely to increase the risk of maternal and fetal morbidity and mortality ^Label.

There is no formal data regarding whether or not angiotensin II may become present in human milk and there is no data available on the effects of angiotensin II on the breastfed child or the effects on milk production ^Label.

The safety and efficacy of angiotensin II in pediatric patients has not yet been established ^Label.

There is no difference in the safety or efficacy between patients less than 65 years old and those 65 years or older when treated with angiotensin II ^Label.

There is no difference in pharmacokinetics between male and female patients ^Label.

The pharmacokinetics of angiotensin II are not expected to be influenced by renal impairment or hepatic impairment ^Label.

Affected organisms

• Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Unlock Additional Data
Levothyroxine	Levothyroxine may increase the vasoconstricting activities of Angiotensin II.
Lidocaine	The risk or severity of hypertension can be increased when Angiotensin II is combined with Lidocaine.
Liothyronine	Liothyronine may increase the vasoconstricting activities of Angiotensin II.
Liotrix	Liotrix may increase the vasoconstricting activities of Angiotensin II.
Patent Blue	The risk or severity of hypotension can be increased when Patent Blue is combined with Angiotensin II.
Thyroid, porcine	Thyroid, porcine may increase the vasoconstricting activities of Angiotensin II.
Thyrotropin alfa	Thyrotropin alfa may increase the vasoconstricting activities of Angiotensin II.

Additional Data Available

Extended Description
Extended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more
Severity
Severity
A severity rating for each drug interaction, from minor to major.
Learn more
Evidence Level
Evidence Level
A rating for the strength of the evidence supporting each drug interaction.
Learn more
Action
Action
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more

Food Interactions

No interactions found.

Products

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Angiotensin II acetate	31L3HS630A	32044-01-2	VBTZKFAHKJXHBA-PIONDTTLSA-N

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Unlock Additional Data
Giapreza	Injection	2.5 mg/1mL	Intravenous	La Jolla Pharmaceutical Company	2018-02-05	Not applicable

Additional Data Available

Application Number
Application Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more
Product Code
Product Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more

Categories

ATC Codes

C01CX09 — Angiotensin ii

• C01CX — Other cardiac stimulants
• C01C — CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
• C01 — CARDIAC THERAPY
• C — CARDIOVASCULAR SYSTEM

Drug Categories

• Amino Acids, Peptides, and Proteins
• Angiotensin II, antagonists & inhibitors
• Angiotensins
• Autacoids
• Biological Factors
• Cardiac Stimulants Excl. Cardiac Glycosides
• Cardiac Therapy
• Cardiovascular Agents
• Hormones
• Hormones, Hormone Substitutes, and Hormone Antagonists
• Inflammation Mediators
• Nerve Tissue Proteins
• Neuropeptides
• Oligopeptides
• Peptide Hormones
• Peptides
• Proteins
• Vasoconstriction
• Vasoconstrictor Agents

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Carboxylic acids and derivatives

Sub Class

Amino acids, peptides, and analogues

Direct Parent

Oligopeptides

Alternative Parents

Tyrosine and derivatives / Phenylalanine and derivatives / Histidine and derivatives / Aspartic acid and derivatives / Isoleucine and derivatives / Valine and derivatives / Proline and derivatives / N-acyl-L-alpha-amino acids / Alpha amino acid amides / Phenylpropanoic acids / Amphetamines and derivatives / Imidazolyl carboxylic acids and derivatives / Pyrrolidinecarboxamides / N-acylpyrrolidines / 1-hydroxy-2-unsubstituted benzenoids / Dicarboxylic acids and derivatives / N-acyl amines / Tertiary carboxylic acid amides / Heteroaromatic compounds / Amino acids / Secondary carboxylic acid amides / Guanidines / Azacyclic compounds / Propargyl-type 1,3-dipolar organic compounds / Carboxylic acids / Carboximidamides / Carbonyl compounds / Hydrocarbon derivatives / Monoalkylamines / Organic oxides / Organopnictogen compounds

show 21 more

Substituents

1-hydroxy-2-unsubstituted benzenoid / 3-phenylpropanoic-acid / Alpha-amino acid amide / Alpha-amino acid or derivatives / Alpha-oligopeptide / Amine / Amino acid / Amino acid or derivatives / Amphetamine or derivatives / Aromatic heteromonocyclic compound / Aspartic acid or derivatives / Azacycle / Azole / Benzenoid / Carbonyl group / Carboxamide group / Carboximidamide / Carboxylic acid / Dicarboxylic acid or derivatives / Fatty acyl / Fatty amide / Guanidine / Heteroaromatic compound / Histidine or derivatives / Hydrocarbon derivative / Imidazole / Imidazolyl carboxylic acid derivative / Isoleucine or derivatives / Monocyclic benzene moiety / N-acyl-alpha amino acid or derivatives / N-acyl-alpha-amino acid / N-acyl-amine / N-acyl-l-alpha-amino acid / N-acylpyrrolidine / N-substituted-alpha-amino acid / Organic 1,3-dipolar compound / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organoheterocyclic compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Phenol / Phenylalanine or derivatives / Primary aliphatic amine / Primary amine / Proline or derivatives / Propargyl-type 1,3-dipolar organic compound / Pyrrolidine / Pyrrolidine carboxylic acid or derivatives / Pyrrolidine-2-carboxamide / Secondary carboxylic acid amide / Tertiary carboxylic acid amide / Tyrosine or derivatives / Valine or derivatives

show 46 more

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

angiotensin II (CHEBI:2719) / Angiotensin [KO:K09821] (C02135)

Chemical Identifiers

UNII

M089EFU921

CAS number

4474-91-3

InChI Key

CZGUSIXMZVURDU-JZXHSEFVSA-N

InChI

InChI=1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)/t28-,33-,34-,35-,36-,37-,38-,40-,41-/m0/s1

IUPAC Name

(3S)-3-amino-3-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(1S,2S)-1-{[(2S)-1-[(2S)-2-{[(1S)-1-carboxy-2-phenylethyl]carbamoyl}pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]carbamoyl}-2-methylbutyl]carbamoyl}-2-(4-hydroxyphenyl)ethyl]carbamoyl}-2-methylpropyl]carbamoyl}-4-[(diaminomethylidene)amino]butyl]carbamoyl}propanoic acid

SMILES

CC[[email protected]](C)[[email protected]](NC(=O)[[email protected]](CC1=CC=C(O)C=C1)NC(=O)[[email protected]@H](NC(=O)[[email protected]](CCCN=C(N)N)NC(=O)[[email protected]@H](N)CC(O)=O)C(C)C)C(=O)N[[email protected]@H](CC1=CN=CN1)C(=O)N1CCC[[email protected]]1C(=O)N[[email protected]@H](CC1=CC=CC=C1)C(O)=O

References

General References

1. Correa TD, Takala J, Jakob SM: Angiotensin II in septic shock. Crit Care. 2015 Mar 16;19:98. doi: 10.1186/s13054-015-0802-3. [PubMed:25886853]

External Links

Human Metabolome Database

HMDB0001035

KEGG Compound

C02135

PubChem Compound

172198

PubChem Substance

347828186

ChemSpider

150504

BindingDB

50236697

RxNav

1999003

ChEBI

58506

ChEMBL

CHEMBL408403

ZINC

ZINC000169676920

Wikipedia

Angiotensin

FDA label

Download (2.45 MB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Active Not Recruiting	Treatment	Body Composition / Exercise Tolerance / Heart Failure / Strength, Muscle / Vasodilation	1
4	Completed	Diagnostic	High Blood Pressure (Hypertension)	1
4	Completed	Other	Dyslipidemia / High Blood Pressure (Hypertension)	1
4	Completed	Prevention	Cardiovascular Heart Disease	1
4	Completed	Prevention	High Blood Pressure (Hypertension) / Infarction, Brain	1
4	Completed	Prevention	Kidney Stones	1
4	Completed	Treatment	High Blood Pressure (Hypertension)	1
4	Completed	Treatment	High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus	1
4	Completed	Treatment	IgA Glomerulonephritis	1
4	Completed	Treatment	IgA Nephropathy	2

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Injection	Intravenous	2.5 mg/1mL
Injection, solution, concentrate	Intravenous	2.5 MG/ML
Injection, solution, concentrate	Intravenous	5 MG/ML

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)	Region
Unlock Additional Data
US9572856	No	2017-02-21	2030-09-20
US9220745	No	2015-12-29	2034-12-18
US9867863	No	2018-01-16	2029-12-16
US10028995	No	2018-07-24	2034-12-18
US10335451	No	2019-07-02	2029-12-16
US10493124	No	2019-12-03	2034-12-18
US10500247	No	2019-12-10	2029-12-16
US10548943	No	2009-12-16	2029-12-16

Additional Data Available

Filed On
Filed On
The date on which a patent was filed with the relevant government.
Learn more

Properties

State

Liquid

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.0156 mg/mL	ALOGPS
logP	-0.87	ALOGPS
logP	-5.3	ChemAxon
logS	-4.8	ALOGPS
pKa (Strongest Acidic)	3.15	ChemAxon
pKa (Strongest Basic)	10.83	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	17	ChemAxon
Hydrogen Donor Count	13	ChemAxon
Polar Surface Area	408.84 Å2	ChemAxon
Rotatable Bond Count	29	ChemAxon
Refractivity	269.81 m3·mol-1	ChemAxon
Polarizability	107.02 Å3	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	0	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

×

Unlock Data

There is additional data available for commercial users including Adverse Effects, Contraindications, and Blackbox Warnings. Contact us to learn more about these and other features.

Learn more

Drug created on October 20, 2016 14:53 / Updated on June 12, 2020 10:53